Transgene raises €65.5M via two-step capital increase

NewsGuard 100/100 Score

Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases, announces that it has raised a total of €65.5 million via a two-step capital increase. The first step of this capital increase was the completion of a rights issue, launched on February 28, 2014, which raised total gross proceeds of €45.5 million through the issuance of 4,553,551 new ordinary shares. The second step carried out on March 24, 2014 was a private placement of €20 million through the issuance of 2 million additional shares.

Rights issue is a major success:

All 4,553,551 new shares were subscribed by the shareholders and purchasers of the preferential subscription rights. The exercise of preferential subscription rights by irrevocable entitlement (souscription à titre irréductible) amounted to 4,378,903 shares. All remaining shares were subscribed on a reducible basis (souscription à titre réductible).

The Institut Mérieux, through its subsidiary TSGH, fully subscribed to its pro rata stake of the rights offering, through the subscription of 2,482,574 shares for a total amount of €24,825,740.

Private placement largely oversubscribed:

Based on demand by a large number of qualified investors, partly outside of France, the Company carried out on March 24, 2014 a placement of 2 million additional shares at a price of €10.00 per share, raising €20 million.

This private placement was carried out in accordance with article L. 225-136 of the French Commercial Code and Resolution 12 of the Shareholders Meeting of June 19, 2013 and was only opened to investors within the meaning of article L. 411-2 II of the French Monetary and Financial Code ("qualified investors and/or small groups of investors acting on their own account"), in France and outside of France, including in the United States.

"These two financing transactions are major successes and indicate investor confidence in Transgene, which is on the brink of an important transformation, with the coming launch of two clinical studies intended for registration," stated Philippe Archinard, Chairman and Chief Executive Officer of Transgene. He added: "We would like to thank our shareholders, who have fully supported the Company in the context of the rights issue, as well as our new investors, most of whom are located outside of France, who gave us their trust. We are committed to lead Transgene to be one of the first European biotechnology companies with an integrated model, including research, development, production, marketing and sales. The confidence of our shareholders is essential to achieve this goal."

"With nearly €100 million in cash, we now have the means to take the next steps in Transgene's corporate development and implement our strategy with confidence," said Stéphane Boissel, Executive Vice President and Chief Financial Officer of Transgene. "Should Novartis exercise its option on TG4010, our cash runway would be extended to at least the end of 2016."


The settlement and listing on Euronext Paris of the new ordinary shares to be issued under the rights issue and of the additional shares issued under the private placement are expected to take place on March 27, 2014. The 6,553,551 new ordinary shares represent 20.55% of Transgene's issued share capital prior to the capital increase and 17.05% post capital increase.

After the settlement, Institut Mérieux's stake in the Company, through its subsidiary TSGH, shall represent 51.95% of the share capital and 64.63% of the voting rights.

The new shares will be fungible with existing shares and will be traded on Euronext Paris (ISIN code FR0005175080). Transgene's ordinary share capital will amount to 87,964,029.39 euros, composed of 38,444,106 shares with a par value of 2.2881 euros.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative breast cancer treatment sequence yields positive results